Dianthus Therapeutics (DNTH) to Release Quarterly Earnings on Thursday

Dianthus Therapeutics (NASDAQ:DNTH) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect Dianthus Therapeutics to post earnings of ($0.69) per share and revenue of $0.86 million for the quarter.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.04. The business had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. On average, analysts expect Dianthus Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Dianthus Therapeutics Trading Up 3.0 %

Shares of DNTH opened at $21.97 on Tuesday. The company’s 50 day simple moving average is $22.44 and its 200-day simple moving average is $24.76. Dianthus Therapeutics has a 12-month low of $18.13 and a 12-month high of $33.77. The firm has a market cap of $650.25 million, a PE ratio of -8.79 and a beta of 1.82.

Wall Street Analyst Weigh In

DNTH has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush restated an “outperform” rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. TD Cowen began coverage on Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating on the stock. Finally, Guggenheim reaffirmed a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $52.14.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.